600222 On Other Exchanges
Symbol
Exchange
Shanghai

henan taloph pharmaceutica-a (600222) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HENAN TALOPH PHARMACEUTICA-A (600222)
\

Related News

No related news articles were found.

henan taloph pharmaceutica-a (600222) Related Businessweek News

No Related Businessweek News Found

henan taloph pharmaceutica-a (600222) Details

Henan Taloph Pharmaceutical Stock Co., Ltd. develops, produces, and sells traditional Chinese and western medicines in China. The company primarily offers its products in the forms of oral liquids, tablets, capsules, infusions, and other forms. Its principal products include Shuanghuanglian oral solution for curing cold; Huperzine A tablet for memory improvement and dementia; and phenol-benzylbenzamine hydrochloride tablets. The company also provides chemical and pharmaceutical raw materials. It serves hospitals, pharmacies, and patients. The company was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd. Henan Taloph Pharmaceutical Stock Co., Ltd. is based in Zhengzhou, China.

1,817 Employees
Last Reported Date: 03/29/19

henan taloph pharmaceutica-a (600222) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

henan taloph pharmaceutica-a
Henan Taloph Pharmaceutical Stock Co.,Ltd Announces Earnings Results for the First Quarter of 2019

Henan Taloph Pharmaceutical Stock Co.,Ltd announced earnings results for the first quarter of 2019. For the period, the company reported basic earnings per share of CNY 0.0227.

Henan Taloph Pharmaceutical Stock Co.,Ltd, Board Meeting, Apr 25, 2019

Henan Taloph Pharmaceutical Stock Co.,Ltd, Board Meeting, Apr 25, 2019. Agenda: To discuss and approve the full text and text of first quarter report of 2019; to discuss the Proposal of Implementing New Accounting Standards; and to discuss the Proposal of Electing Vice Chair of Directorate, Appointing Senior Management Members and Changing Duties.

Henan Taloph Pharmaceutical Stock Co.,Ltd to Report Q1, 2019 Results on Apr 27, 2019

Henan Taloph Pharmaceutical Stock Co.,Ltd announced that they will report Q1, 2019 results on Apr 27, 2019

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

600222 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600222.
View Industry Companies
 

Industry Analysis

600222

Industry Average

Valuation 600222 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HENAN TALOPH PHARMACEUTICA-A, please visit www.taloph.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.